Marie Linder

List of Publications by Year
in descending order

36 papers	**646** citations	1051969 **10** h-index	651938 **25** g-index
36 all docs	**36** docs citations	**36** times ranked	**1024** citing authors

#	Article	IF	Citations
1	Patient characteristics and safety outcomes in new users of ticagrelor and clopidogrelâ€"An observational cohort study in Sweden. Pharmacoepidemiology and Drug Safety, 2022, 31, 235-246.	0.9	1
2	Rationale and performances of a data-driven method for computing the duration of pharmacological prescriptions using secondary data sources. Scientific Reports, 2022, 12, 6245.	1.6	3
3	A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder. Current Medical Research and Opinion, 2021, 37, 867-877.	0.9	3
4	Use of nonâ€insulin antidiabetic drugs in children and young adults â€" A Scandinavian drug utilization study from 2010â€"2019. British Journal of Clinical Pharmacology, 2021, 87, 4470-4475.	1.1	1
5	Societal impact for patients with psoriasis: A nationwide Swedish register study. JAAD International, 2021, 3, 63-75.	1.1	9
6	Using epidemiological methods to quantify the risk of serious infections in children with atopic dermatitis. British Journal of Dermatology, 2021, 185, 11-12.	1.4	0
7	Use of intravenous iron and risk of anaphylaxis: A multinational observational postâ€authorisation safety study in Europe. Pharmacoepidemiology and Drug Safety, 2021, 30, 1447-1457.	0.9	5
8	Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study. Drug Safety, 2021, 44, 899-915.	1.4	6
9	Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including diseaseâ€specific treatments: a French nationwide cohort study. British Journal of Haematology, 2021, 195, 456-465.	1.2	9
10	Lessons Learned Using Realâ€World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune Thrombocytopenia. Clinical Pharmacology and Therapeutics, 2021, 110, 1570-1578.	2.3	2
11	The use of uncertain exposureâ€"A method to define switching and addâ€on in pharmacoepidemiology. Pharmacoepidemiology and Drug Safety, 2021, , .	0.9	1
12	Influence of statinâ€potency on the risk of kidney disease â€" A nationwide cohort study using laboratory data. Pharmacoepidemiology and Drug Safety, 2021, 30, 210-219.	0.9	1
13	Methods for constructing treatment episodes and impact on exposure-outcome associations. European Journal of Clinical Pharmacology, 2020, 76, 267-275.	0.8	14
14	Cancer risk in patients with primary immune thrombocytopenia â€" A Swedish nationwide register study. Cancer Epidemiology, 2020, 69, 101806.	0.8	6
15	<p>The Occurrence of Metabolic Risk Factors Stratified by Psoriasis Severity: A Swedish Population-Based Matched Cohort Study</p>. Clinical Epidemiology, 2020, Volume 12, 737-744.	1.5	5
16	Risk of common infections among individuals with psoriasis in Sweden: A nationwide cohort study comparing secukinumab to ustekinumab. Pharmacoepidemiology and Drug Safety, 2020, 29, 1562-1569.	0.9	8
17	<p>Assessing Safety of Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors and Vitamin K Antagonists in Patients with Atrial Fibrillation: A Nation-Wide Propensity Score Matched Cohort from Sweden</p>. Clinical Epidemiology, 2020, Volume 12, 1029-1038.	1.5	2
18	Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication. European Journal of Clinical Pharmacology, 2020, 76, 867-876.	0.8	17

#	Article	IF	Citations
19	Adult height is associated with risk of cancer and mortality in 5.5 million Swedish women and men. Journal of Epidemiology and Community Health, 2019, 73, 730-736.	2.0	11
20	Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia â€" Results from two nationwide cohorts. Thrombosis Research, 2019, 178, 124-131.	0.8	23
21	\<p\>Exposure to antimuscarinic medications for treatment of overactive bladder and risk of lung cancer and colon cancer\</p\>. Clinical Epidemiology, 2019, Volume 11, 133-143.	1.5	9
22	Patient characteristics when starting treatment and patterns of treatment in adults with chronic immune thrombocytopenia. Blood Coagulation and Fibrinolysis, 2019, 30, 350-356.	0.5	3
23	Methods for timeâ€varying exposure related problems in pharmacoepidemiology: An overview. Pharmacoepidemiology and Drug Safety, 2018, 27, 148-160.	0.9	89
24	Young patients with risk factors prevalent in the elderly &ndash;&nbsp;
differences in comorbidity depending on severity of psoriasis: a nationwide cross-sectional study in Swedish health registers. Clinical Epidemiology, 2018, Volume 10, 705-715.	1.5	10
25	Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany. Pharmacoepidemiology and Drug Safety, 2018, 27, 953-961.	0.9	2
26	Risk Factors of Thrombosis in Adults with Primary Immune Thrombocytopenia. a French Nationwide Cohort Study. Blood, 2018, 132, 3745-3745.	0.6	2
27	Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. Pharmacoepidemiology and Drug Safety, 2017, 26, 615-624.	0.9	14
28	Palivizumab Exposure and the Risk of Atopic Dermatitis, Asthma and Allergic Rhinoconjunctivitis: A Cross-National, Population-Based Cohort Study. Paediatric Drugs, 2017, 19, 155-164.	1.3	5
29	Pharmacological agents preceding a diagnosis of immune thrombocytopenia in adult patients developing the chronic form: A Swedish national register study. Thrombosis Research, 2017, 160, 27-31.	0.8	1
30	Increased susceptibility to infections before the diagnosis of immune thrombocytopenia. Journal of Thrombosis and Haemostasis, 2016, 14, 807-814.	1.9	20
31	Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence. European Journal of Clinical Pharmacology, 2016, 72, 349-357.	0.8	11
32	Children with hemodynamically significant congenital heart disease can be identified through population-based registers. Clinical Epidemiology, 2015, 7, 119.	1.5	10
33	Incidence rates of atopic dermatitis, asthma, and allergic rhinoconjunctivitis in Danish and Swedish children. Journal of Allergy and Clinical Immunology, 2015, 136, 360-366.e2.	1.5	116
34	Use of palivizumab is underestimated in the Swedish Prescribed Drug Register – implications for register-based drug studies. Clinical Epidemiology, 2014, 7, 45.	1.5	8
35	Precision of prediction in second-order calibration, withÂfocus on bilinear regression methods. Journal of Chemometrics, 2002, 16, 12-27.	0.7	89
36	Second-order calibration: bilinear least squares regression and a simple alternative. Chemometrics and Intelligent Laboratory Systems, 1998, 42, 159-178.	1.8	130